Björn Dahlöf

Research.com Recognitions

• 2023 - Research.com Medicine in Sweden Leader Award

Overview

Best Publications

• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial

  Lennart Hansson;Alberto Zanchetti;S George Carruthers;Björn Dahlöf

  8738
  Citations

• Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  Björn Dahlöf;Richard B Devereux;Sverre E Kjeldsen;Stevo Julius

  7598
  Citations

• Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

  Peter S Sever;Björn Dahlöf;Neil R Poulter;Hans Wedel

  4662
  Citations

• Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

  Björn Dahlöf;Peter S Sever;Neil R Poulter;Hans Wedel

  3434
  Citations

• Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

  Lennart Hansson;Lars H Lindholm;Leo Niskanen;Jan Lanke

  3037
  Citations

• Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

  Kenneth Jamerson;Michael A. Weber;George L. Bakris;Björn Dahlöf

  3015
  Citations

• Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

  B. Dahlöf;L. Hansson;L.H. Lindholm;B. Scherstén

  2627
  Citations

• Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension.

  Peter M Rothwell;Sally C Howard;Eamon Dolan;Eoin O'Brien

  2330
  Citations

• Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

  Lars H Lindholm;Hans Ibsen;Björn Dahlöf;Richard B Devereux

  2247
  Citations

• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  Lennart Hansson;Lars H Lindholm;Tord Ekbom;Björn Dahlöf

  2134
  Citations

• Guidelines for the management of atrial fibrillation

  A. John Camm;Paulus Kirchhof;Gregory Y H Lip;Ulrich Schotten

  2032
  Citations

• Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies.

  Björn Dahlöf;Kjell Pennert;Lennart Hansson

  1422
  Citations

• Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

  Lennart Hansson;Thomas Hedner;Per Lund-Johansen;Sverre Erik Kjeldsen

  1328
  Citations

• Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke

  Ralph L. Sacco;Hans-Christoph Diener;Salim Yusuf;Daniel Cotton

  1245
  Citations

• Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study

  Kristian Wachtell;Mika Lehto;Eva Gerdts;Michael H. Olsen

  1154
  Citations

• Prognostic significance of left ventricular mass change during treatment of hypertension

  Richard B Devereux;Kristian Wachtell;Eva Gerdts;Krister K. Boman

  1126
  Citations

• Telmisartan to prevent recurrent stroke and cardiovascular events.

  Salim Yusuf;Salim Yusuf;Hans-Christoph Diener;Ralph L. Sacco;Daniel Cotton

  1020
  Citations

• Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

  Peter M Rothwell;Sally C Howard;Eamon Dolan;Eoin O'Brien

  853
  Citations

• Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

  Peter M. Okin;Richard B. Devereux;Sverker Jern;Sverre E. Kjeldsen

  818
  Citations

• Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA): A Multicentre Randomised Controlled Trial

  Peter S Sever;Björn Dahlöf;Neil R Poulter;Hans Wedel

  805
  Citations